Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia:a Multi-center, Open-label, Non-randomised, Single-arm Phase Ⅰ Clinical Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06326021
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:15.262207+00:00
Published At
2026-03-10T00:00:00+00:00
Record Updated At
2026-03-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Refractory/Relapsed Acute Myeloid Leukaemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-10"
protocolSection.identificationModule.nctId
"NCT06326021"
protocolSection.identificationModule.officialTitle
"Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia\uff1aa Multi-center, Open-label, Non-randomised, Single-arm Phase \u2160 Clinical Trial"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Refractory/Relapsed Acute Myeloid Leukaemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.